



**E. Allan Gabor**  
**President, Merck China**

E. Allan Gabor has been appointed as the President of Merck China since February 1st, 2018. He is also a permanent member of Merck's Performance Materials Leadership Team (PMLT), responsible for topics in China. As President of Merck China, he is responsible for developing and driving growth strategies in this key country and building on the company's 350-year presence and reputation. China is one of the Group's top-selling countries with all the three Business Sectors of Merck developing rapidly. Prior to this role, he was the President of Asia Pacific for the biopharma business of the Merck Group. He assumed this position since January 2016.

Before Mr. Gabor was promoted to President of the Asia-Pacific region, he was the President and CEO for the biopharma business in China and was instrumental in expanding Merck's Asian footprint with a series of investments including establishing Merck's new €170 million world-class pharmaceutical manufacturing facility located in the Nantong as well as building an extensive network of collaborations with leading academic and medical institutions, thereby enhancing Merck's commercial presence in China.

Prior to joining Merck, Mr. Gabor spent 25 years at Pfizer in leadership roles including Chairman and General Manager for China, and Regional President for North Asia, Russia, India, Turkey and Eastern Europe, across many different businesses and geographies with responsibilities within sales and marketing,



strategy, mergers and acquisitions and general management. Mr. Gabor successfully directed the launch of many of Pfizer's innovative medicines into China and opened the China Regional Investment Center and a state of the art research and development center in Shanghai.

In recognition of his tireless contribution towards the economic construction, social development and international exchange and cooperation of Shanghai, Mr. Gabor has been awarded the Magnolia (Baiyulan) Award twice by the Shanghai municipal government.

Mr. Gabor is a highly seasoned executive with an extensive knowledge of strategy, commercial operations and business development. He holds a BA in Communications from the College of Wooster and pursued further education at the University of Tennessee and Harvard Business School.

安高博自2018年2月开始担任默克中国区总裁。与此同时，安高博也成为默克高性能材料全球管理团队中的常任成员，负责中国的事务。作为默克中国区总裁，他负责制定中国的发展战略、驱动增长，并负责在传承和发扬公司350年的悠久历史和良好声誉。而中国是集团三个业务板块销售业绩最高的国家之一。

安高博在此任之前担任默克集团生物制药业务亚太区的总裁两年时间，而在升任亚太区总裁前，安高博是默克中国生物制药业务总裁和首席执行官，他开展的一系列投资活动大大拓展了默克在亚洲的业务，其中包括投资1.7亿欧元在南通新建默克世界级制药工厂，以及与一流的学术和医疗机构建立广泛的协作网络来助推默克在中国的商业活动。加入默克之前，安高博在辉瑞公司担任领导职务长达25年，其中包括担任辉瑞制药有限公司中国董事长兼总经理，以及北亚、俄罗斯、印度、土耳其和东欧等地的区域总裁。他的工作领域涉及多个业务部门并跨越不同地区，负责过销售与市场、战略、兼并与收购和综合管理等多项工作。他曾成功主导辉瑞的多款新药在中国的上市进程，并在上海设立了辉瑞总部暨辉瑞投资有限公司和最先进的研发中心。

为表彰安高博先生对上海经济建设、社会发展和国际交流与合作的不懈努力和杰出贡献，上海市政府两度授予他白玉兰奖。

安高博是一位经验非常丰富的企业管理者，对战略、商业运作和业务发展等都有广泛的了解。他毕业于伍斯特学院，获得传播学学士学位，并曾在田纳西大学和哈佛大学商学院深造。